Analytical Data
-
Gene name
GZMB
- Application
-
Alternative Names
(C11)(CTLA-1)(Cathepsin G-like 1)(CTSGL1)(Cytotoxic T-lymphocyte proteinase 2)(Lymphocyte protease)(Fragmentin-2)(Granzyme-2)(Human lymphocyte protein)(HLP)(SECT)(T-cell serine protease 1-3E)
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10144
-
Expression Region
1-247aa
-
AA Sequence
MQPILLLLAFLLLPRADAGEIIGGHEAKPHSRPYMAYLMIWDQKSLKRCGGFLIQDDFVLTAAHCWGSSINVTLGAHNIKEQEPTQQFIPVKRPIPHPAYNPKNFSNDIMLLQLERKAKRTRAVQPLRLPSNKAQVKPGQTCSVAGWGQTAPLGKHSHTLQEVKMTVQEDRKCESDLRHYYDSTIELCVGDPEIKKTSFKGDSGGPLVCNKVAQGIVSYGRNNGMPPRACTKVSSFVHWIKKTMKRH
-
Molecular Weight
54.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Granzyme B (GZMB) is a serine protease predominantly produced by cytotoxic T lymphocytes and natural killer (NK) cells, playing a critical role in the immune response by inducing apoptosis in target cells. Research on GZMB has garnered attention due to its dual functionality in both immune regulation and its potential involvement in various diseases, including cancer and autoimmune disorders. The understanding of GZMB's mechanisms, including its activation pathways and substrate specificity, is essential for exploring its therapeutic applications. The production of recombinant GZMB has facilitated advances in this research, allowing for detailed studies of its enzymatic properties, interactions with other proteins, and its role in immune-mediated cytotoxicity. By utilizing recombinant DNA technology, scientists can produce large quantities of GZMB for in vitro and in vivo experiments, providing insights into its biological functions and paving the way for novel therapeutic strategies aimed at modulating immune responses or targeting malignant cells. Ongoing studies focus on optimizing recombinant GZMB’s efficacy and exploring its potential as a biomarker or therapeutic agent in various clinical settings.
